https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relacorilant-nab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or?
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian...
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
nab paclitaxel
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.662865/full
Frontiers | Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical...
Introduction/Purpose: Relacorilant is a selective glucocorticoid receptor modulator (SGRM) with no progesterone receptor activity. We evaluated the efficacy ...
glucocorticoid receptorfrontiersrelacorilantselectivemodulator
https://www.hmpgloballearningnetwork.com/site/onc/videos/relacorilant-plus-nab-paclitaxel-patients-platinum-resistant-ovarian-cancer
Relacorilant Plus Nab-Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with...
nab paclitaxelfor patientsrelacorilantplus